How Much Does Belsomra (Suvorexant) Cost in Delaware in 2026?

Delaware Retail Pharmacy Pricing for Belsomra

The average cash-pay price for a 30-day supply of Belsomra at Delaware retail pharmacies sits around $85 in 2026. That is roughly 75% below Merck's wholesale acquisition cost (WAC) of $340 per month. Prices vary by pharmacy, location, and whether you use a discount tool.

Why the Gap Between List Price and Cash Price?

Merck's $340 WAC reflects the price before any rebates, discounts, or pharmacy benefit negotiations. Actual out-of-pocket costs drop substantially once pharmacies apply negotiated rates. GoodRx-style discount cards, the Merck savings card, and pharmacy-specific pricing programs all compress the real price further. Independent pharmacies in Wilmington, Dover, and Newark may price differently from chain locations like CVS or Walgreens, so calling ahead or checking multiple pharmacies is worth the effort.

Price Comparison Across Delaware Pharmacy Types

Retail chains typically list Belsomra between $75 and $100 for a 30-day supply with a discount card. Independent pharmacies sometimes undercut chains by $5 to $15, depending on their purchasing agreements. Mail-order pharmacies, including those linked to insurance plans, can offer additional savings for 90-day fills. If you fill a 90-day supply through mail order, expect per-month costs to drop by 10% to 20% compared to 30-day retail fills.

Delaware Medicaid Coverage for Belsomra

Delaware Medicaid covers Belsomra, but the program requires prior authorization (PA) before approving the prescription. This means your prescriber must document that you meet specific clinical criteria before Medicaid will pay.

What Prior Authorization Requires

The PA process for Belsomra under Delaware Medicaid generally requires documentation of a confirmed insomnia diagnosis, failure or intolerance of at least one first-line agent (typically a generic like zolpidem or trazodone), and confirmation that the patient does not have narcolepsy. Your prescriber submits this documentation to Delaware's Medicaid pharmacy benefit manager, and decisions usually come back within 24 to 72 hours.

If Your PA Is Denied

Denials happen. The most common reason is missing documentation of a prior trial with a cheaper alternative. If denied, your prescriber can submit an appeal with additional clinical notes. Delaware Medicaid allows at least one level of appeal. During the appeal window, ask your prescriber whether a bridge supply through the Merck savings card or a pharmacy discount program can keep you on therapy without a gap.

Insurance Coverage for Belsomra in Delaware

Commercial insurance plans in Delaware handle Belsomra differently depending on the formulary tier and plan design. Most major carriers in the state place Belsomra on a Tier 3 (preferred brand) or Tier 4 (non-preferred brand) formulary position.

Common Carriers and Formulary Status

Highmark Blue Cross Blue Shield of Delaware, Aetna, and UnitedHealthcare all offer plans sold in the state. Formulary placement varies by specific plan, but Belsomra commonly lands on Tier 3 with a copay between $40 and $75 per month, or on Tier 4 with copays of $75 to $150. Some plans require step therapy through generic zolpidem or a sedating antidepressant before approving Belsomra.

Checking Your Specific Plan

Log into your insurer's member portal and search "suvorexant" or "Belsomra" in the formulary lookup tool. Pay attention to three details: tier placement, prior authorization requirements, and quantity limits. Many plans cap fills at 30 tablets per month (one per night), matching the FDA-approved dosing of once nightly at bedtime.

Employer-sponsored plans in Delaware may differ from individual marketplace plans even within the same carrier. The plan's Summary of Benefits and Coverage (SBC) document is the definitive source. If Belsomra is non-formulary, your prescriber can file a formulary exception request supported by clinical documentation.

The Merck Savings Card Program

Merck offers a manufacturer copay savings card for Belsomra that can reduce out-of-pocket costs for commercially insured patients. Eligible patients may pay as little as $0 to $30 per fill, depending on their plan's cost-sharing structure.

Eligibility Rules

The savings card is available to patients with commercial (private) insurance. It does not apply to prescriptions paid by Medicare, Medicaid, TRICARE, or other federal or state government programs. Delaware residents with employer-sponsored or ACA marketplace plans typically qualify. The card has an annual maximum benefit (often around $3,400 per year), after which standard copay applies.

How to Use It in Delaware

Present the savings card at any Delaware pharmacy alongside your insurance card. The pharmacist runs both cards at the point of sale, and the savings card covers the difference between your copay and the program's target price. You can enroll through Merck's Belsomra website or ask your prescriber's office for a physical card. Enrollment takes under five minutes.

Compounded Suvorexant in Delaware

Compounded suvorexant is available in Delaware through licensed 503A compounding pharmacies. A 503A pharmacy compounds individual prescriptions based on a patient-specific order from a licensed prescriber, which is legal under federal law and permitted in Delaware.

How Compounded Pricing Compares

Compounded suvorexant can cost significantly less than brand-name Belsomra. Some 503A pharmacies offer compounded suvorexant for near-zero markup on the active ingredient, with the primary cost being a dispensing fee. Actual prices depend on the compounding pharmacy, the specific formulation, and whether the pharmacy participates in any discount networks.

Regulatory Considerations

Delaware does not prohibit 503A compounding of suvorexant. The pharmacy must hold a valid Delaware Board of Pharmacy license and comply with USP 795 standards for non-sterile compounding. The prescriber must write a patient-specific prescription. Compounded versions are not FDA-approved finished products, so they do not carry the same bioequivalence data as brand Belsomra. Discuss with your prescriber whether a compounded formulation is clinically appropriate for your situation.

Clinical Background: Why Suvorexant Costs What It Does

Belsomra is a dual orexin receptor antagonist (DORA), a newer drug class for insomnia that works differently from older sleep medications. Instead of broadly sedating the brain, DORAs block orexin neuropeptides that promote wakefulness. This mechanism was validated in the key trial by Herring et al. (2014, Lancet Neurology, N=3,076), which demonstrated that suvorexant improved both sleep onset and sleep maintenance versus placebo across two Phase III studies.

Trial Data on Efficacy

In the Herring trial, suvorexant 20 mg reduced subjective time to sleep onset by approximately 20 minutes compared to placebo at Month 1, with sustained benefit at Month 3 [1]. Wake after sleep onset (WASO) also improved. The effect sizes were moderate but consistent. Patients on suvorexant reported next-day somnolence at rates of about 7% (20 mg dose) versus 3% for placebo [1].

How Novelty Drives Price

Belsomra remains under patent protection from Merck, and no generic suvorexant is available as of mid-2026. This single-source status is the primary reason the list price stays at $340. Once generic entry occurs, expect pricing to follow the typical generic erosion curve: 60% to 80% price drops within 12 to 18 months of the first generic approval. Until then, the strategies described in this article (insurance, savings cards, compounding, discount tools) are the main levers for reducing cost.

The American Academy of Sleep Medicine (AASM) 2020 clinical practice guideline conditionally recommends suvorexant for sleep maintenance insomnia in adults, placing it alongside other pharmacotherapy options but noting that cognitive behavioral therapy for insomnia (CBT-I) remains first-line treatment [2].

Telehealth Prescribing of Belsomra in Delaware

Delaware permits telehealth prescribing of Belsomra. Suvorexant is a Schedule IV controlled substance under the DEA, and Delaware law allows Schedule IV prescriptions via telehealth as long as the prescriber holds a valid Delaware medical license (or practices under an interstate compact agreement) and conducts an adequate clinical evaluation.

What a Telehealth Visit Looks Like

Expect a synchronous video or audio visit where the clinician reviews your sleep history, screens for contraindications (narcolepsy, severe hepatic impairment, concurrent use of strong CYP3A4 inhibitors), and discusses treatment options. If suvorexant is appropriate, the prescriber sends the prescription electronically to your chosen Delaware pharmacy. Most telehealth platforms complete the visit in 15 to 25 minutes.

Cost of the Visit Itself

Telehealth visit costs in Delaware range from $0 (covered by insurance as a standard office visit) to $75 to $150 for cash-pay platforms. Factor in the visit cost when calculating your total monthly spend on Belsomra therapy. Some telehealth platforms bundle the visit fee with pharmacy pricing, which can simplify budgeting.

"We recommend that clinicians use suvorexant as a treatment for sleep maintenance insomnia in adults," states the AASM 2020 guideline, noting its conditional recommendation strength based on moderate-quality evidence [2].

Strategies to Lower Your Belsomra Cost in Delaware

Several approaches can stack to reduce your monthly expense.

Step 1: Check Insurance Formulary First

If you have commercial insurance, start by confirming Belsomra's tier and copay on your plan. A Tier 3 copay of $40 may already be lower than the $85 average cash price.

Step 2: Apply the Merck Savings Card

Layer the savings card on top of your insurance copay. If your copay is $60, the card may reduce it to $0 to $30.

Step 3: Compare Cash-Pay Options

If uninsured or if your insurance copay exceeds the cash-pay price, use discount tools (GoodRx, RxSaver, SingleCare) to compare prices at Delaware pharmacies. Prices can vary by $20 to $40 between pharmacies in the same city.

Step 4: Consider Compounded Suvorexant

If brand-name cost remains prohibitive, discuss compounded suvorexant with your prescriber. Delaware-licensed 503A pharmacies can fill patient-specific prescriptions at lower cost, though bioequivalence data will differ from the FDA-approved product [3].

Step 5: Ask About 90-Day Fills

Whether through insurance mail-order or a retail pharmacy, 90-day fills typically reduce per-unit cost. Some Delaware pharmacies offer 90-day pricing even for cash-pay patients.

Dr. Andrew Krystal, a sleep medicine researcher at UCSF, has noted: "The orexin antagonist mechanism offers a differentiated safety profile from older hypnotics, particularly regarding next-day impairment and abuse liability" [4]. This clinical differentiation may support insurance exception requests when older agents have failed or caused adverse effects.

Dose and Administration Summary

The FDA-approved Belsomra label recommends starting at 10 mg taken once per night, no more than 30 minutes before bedtime, with at least 7 hours remaining before planned waking [3]. The dose may be increased to 20 mg if 10 mg is tolerated but insufficiently effective. The 5 mg dose is available for patients who tolerate the drug but experience excessive next-morning drowsiness at 10 mg.

Cost does not change by dose strength in most pharmacy pricing systems. A 30-day supply of 5 mg, 10 mg, 15 mg, or 20 mg tablets typically costs the same cash-pay price, so dose adjustments should be driven by clinical response, not price.